Hui Zhang, PhD

Neurocrine Biosciences, Inc., San Diego, California

  • 2Articles
  • 2.4KReads
  • 2006–2026Active
  • 21Collaborators

About

Hui Zhang, PhD is affiliated with Neurocrine Biosciences, Inc., San Diego, California. Hui Zhang has authored or co-authored 2 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2006 and 2026. Their work focuses on Metabolic Disorders, Schizophrenia/Schizoaffective Disorders, and Tardive Dyskinesia.

Publications

JCP
Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials
Narrative Review

Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials

April 29, 2026

The TDIS followed a similar trajectory to other clinician- and patient-reported outcomes measured in tardive dyskinesia clinical trials, and a change of 4 points in total score is considered...
, , , et al
JCP
Original Research

Glucose Metabolism in Patients With Schizophrenia Treated With Olanzapine or Quetiapine: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis

May 15, 2006

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe